Meghmani Organics LtdQ4 FY24

Meghmani Organics Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹59.55P/E: 23.6Market Cap: ₹1.5K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

No

Order

N/A

Capex

No

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Agrochemical segment expected to see demand improvement from Q2 FY25, with better volumes and prices, leading to improved profitability, especially from H2 FY25 onwards.
  • Pigment segment prices have bottomed out; gradual price increases and volume growth expected in FY25 as demand recovers.
  • Nano Urea segment to start contributing meaningful revenue from FY25; scaling expected over 2-3 years with ongoing farmer demonstrations and market education.
  • Titanium Dioxide business targeting domestic market growth under Atmanirbhar Bharat, balancing export and domestic revenue streams; capacity utilization expected to reach 60%+ from Q1 FY25.
  • Overall revenue mix to balance between exports (75% currently) and growing domestic market contributions.
  • Long-term growth prospects remain intact due to state-of-the-art infrastructure, wider product range, and geographical reach.
  • Market normalization and inventory destocking expected to drive volume and value improvements in FY25.

See what Meghmani Organics Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • Meghmani Organics Limited has already completed all major capex before the recent downturn.
  • No major capex is planned in the next one to two years.
  • Hence, no significant new debt or equity fundraising is expected in the near future.
  • The company plans to focus on debt reduction, with INR140 crores repayment scheduled in the current financial year.
  • Further debt reduction is anticipated in the next financial year.
  • Overall, Meghmani aims to be in a reasonable debt position within the next one to two years without requiring new fundraising.

See what Meghmani Organics Ltd management said on order book — free account, 30 seconds.

Capex plans

No
  • Meghmani Organics has completed all major capex before the recent downturn; no significant new capex planned for the next 1-2 years.
  • Current infrastructure, including state-of-the-art plants in crop protection and pigment segments, is ready to leverage market improvement.
  • A Co-gen power plant has been commissioned at the titanium dioxide facility to reduce energy costs.
  • The nano urea plant was commissioned recently (March 2024), with plans to expand product offerings in fertilizer, biofertilizer, and biostimulant categories to build a comprehensive agriculture solution.
  • No mention of strategic investments beyond expanding the product basket and improving manufacturing capabilities.
  • Focus remains on optimizing utilization of existing capacity and reducing debt over the next two years rather than new capital investments.

Track Meghmani Organics Ltd — get its next earnings analysis in your feed

How does Meghmani Organics Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature
ThisMeghmani Organics Ltd
Rev 3Mar 3

How does Meghmani Organics Ltd rank in Fertilizers & Agrochemicals?

Compare Meghmani Organics Ltd against every Fertilizers & Agrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

Others in Fertilizers & Agrochemicals this season

  • Bhagiradha Chemicals & Industries Ltd (Q2 FY26)

    140.1 crore, up 35% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q2 FY26 investor presentation — and how it ran

  • Bhagiradha Chemicals & Industries Ltd (Q3 FY26)

    114.0 crore, up 11% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q3 FY26 investor presentation — and how it ran

  • Advance Agrolife Ltd (Q3 FY26)

    Q3 FY26 revenue from operations was ₹1,338 million, up 18% year-on-year (YoY) from ₹1,134 million in Q3 FY25 (Pages 23-24). Key investor presentation takeaways

  • Dhansa Labs Ltd (Q4 FY26)

    120-140 crores in additional annual revenue upon stabilization, with initial revenue of around Rs. Key concall takeaways from Dhansa Labs's Q4 FY26 earnings…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →